Search Results

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list.

Biodesix, Inc., a leading diagnostic solutions company with a focus in lung disease, announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences.

Biodesix, Inc. announced that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the 2024 RBCCM Global Healthcare Conference, which will be held from May 14-15, 2024.

Biodesix, Inc., a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented at the 2024 American Thoracic Society International Conference in San Diego, California.

Biodesix, Inc., a leading diagnostic solutions company with a focus in lung disease, announced that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8.

Biodesix, Inc., a leading diagnostic solutions company with a focus in lung disease, announced its financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.

Biodesix, Inc. today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share.